On April 14, scientists published the first detailed protein map of two subtypes of pain-sensing neurons, identifying over 6,000 proteins and pinpointing the enzyme B3GNT2 as a promising target for new painkillers that could operate without the systemic side effects of current medications.
“To develop them, we first need to understand exactly how sensory nerve cells trigger pain at the molecular level – which proteins are involved,” said Professor Gary Lewin, head of the Molecular Physiology of Somatosensory Perception group at the Max Delbrück Center in Berlin.The breakthrough comes as one in five people worldwide suffers from chronic inflammatory pain, and existing drugs provide little relief for two-thirds of those affected, creating urgent demand for entirely new therapeutic approaches. Using Deep Visual Proteomics – a method co-developed by systems biologist Dr. Fabian Coscia – the team combined high-resolution protein mapping with electrophysiology to functionally identify neuronal subtypes before analyzing their full protein profiles, revealing signaling pathways previously unknown to science. <!– /wp:paragraph> wp:paragraph > Lead author Dr. Sampurna Chakrabarti, now leading her own research group on infection and nociception mechanisms at the Helmholtz Centre for Infection Research in Braunschweig, emphasized that while transcriptomes of subtypes were known, the actual functional drivers – the proteins built from RNA blueprints – had never been examined in such detail for these nociceptors. /wp:paragraph> wp:paragraph > Parallel advances are emerging in immunology: on April 15, OSE Immunotherapeutics unveiled a novel monoclonal antibody targeting the FPR2 receptor, designed to activate the body’s natural inflammation-resolution pathways by reprogramming pro-inflammatory macrophages. /wp:paragraph> wp:paragraph > This strategy draws on findings from Freiburg University Hospital showing that chronic infections like hepatitis C can permanently alter T-helper cells, leaving behind a kind of immunological memory that sustains inflammation long after the pathogen is gone – meaning effective treatment must go beyond eliminating the original trigger. /wp:paragraph> wp:paragraph > Yet as laboratory science accelerates, clinicians warn of silent threats within the body. Physicians at the 2025-established Liver Centre in Ebersberg stressed in mid-April how fatty liver disease, driven by sugar- and fat-rich diets plus alcohol, can trigger a fatal cascade from fibrosis to cirrhosis and significantly elevated cancer risk.
Key detail: The protein map identifies B3GNT2 as a druggable enzyme that could enable painkillers targeting the source of inflammatory pain without widespread side effects.
/wp:html> wp:paragraph > But scientific promise risks colliding with policy reality. A planned German healthcare reform proposing higher patient co-payments could restrict access to these extremely innovations, threatening to undermine therapeutic progress at the moment it becomes tangible. /wp:paragraph> wp:paragraph > Researchers emphasize that breakthroughs in molecular targeting and inflammation resolution are meaningless if the people who need them most cannot afford or access the resulting treatments – a tension now playing out in laboratories, clinics and legislative chambers across Germany. /wp:paragraph> wp:heading > How soon could these new pain therapies reach patients?
/wp:heading> wp:paragraph > While the protein map and antibody prototype represent significant early-stage progress, clinical development typically takes years; no timeline for patient availability was specified in the sources.
What makes visceral fat especially dangerous in chronic inflammation?
/wp:heading> wp:paragraph > Visceral fat, stored deep in the abdomen around organs, actively secretes inflammatory compounds and is strongly linked to the progression from fatty liver to fibrosis, cirrhosis and increased cancer risk – unlike subcutaneous fat, it poses direct metabolic harm. /wp:paragraph>–>Auch interessant
